EUR-1008 pancreatic enzyme replacement is safe and effective in patients with cystic fibrosis and pancreatic insufficiency

Journal of Cystic Fibrosis

Volumn 8, Issue 6, 2009, Pages 405-417

  Wooldridge, Jamie L ^a   Heubi, James E ^a   Amaro Galvez, Rodolfo ^b   Boas, Steven R ^c   Blake, Kathryn V ^d   Nasr, Samya Z ^e   Chatfield, Barbara ^f   McColley, Susanna A ^g   Woo, Marlyn S ^h   Hardy, Karen A ⁱ   Kravitz, Richard M ^j   Straforini, Cristina ^k   Anelli, Marco ^k   Lee, Candace ^l  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

^c Chicago CF CARE Specialists   (United States)

^d NEMOURS CHILDREN S CLINIC   (United States)

^e UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^f UNIVERSITY OF UTAH   (United States)

^g CHILDREN'S MEMORIAL HOSPITAL   (United States)

^h CHILDREN S HOSPITAL LOS ANGELES   (United States)

ⁱ CHILDREN S HOSPITAL OAKLAND   (United States)

^j DUKE UNIVERSITY MEDICAL CENTER   (United States)

^k Eurand SpA   (Italy)

^l Eurand Inc   (United States)

more..

Author keywords

Cystic fibrosis; Malabsorption; Overfill; Pancreatic enzyme replacement; Pancreatic insufficiency; Pancrelipase

Indexed keywords

EUR 1008; LIPID; NITROGEN; PANCRELIPASE; PLACEBO; UNCLASSIFIED DRUG; ZENPEP;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ABNORMAL FECES; ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONTUSION; COUGHING; CROSSOVER PROCEDURE; CYSTIC FIBROSIS; DECREASED APPETITE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME REPLACEMENT; FECES; FECES ANALYSIS; FEMALE; FLATULENCE; HEADACHE; HEMOPTYSIS; HUMAN; INCIDENCE; LIPID ABSORPTION; MALABSORPTION; MALE; METABOLIC DISORDER; MULTICENTER STUDY; NUTRITIONAL DISORDER; OPEN STUDY; OUTCOME ASSESSMENT; PANCREAS EXOCRINE INSUFFICIENCY; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRESCHOOL CHILD; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SATIETY; SCHOOL CHILD; SIDE EFFECT; STEATORRHEA; TREATMENT OUTCOME; WEIGHT REDUCTION;

ADOLESCENT; CHILD; CHOLESTEROL; CROSS-OVER STUDIES; CYSTIC FIBROSIS; EXOCRINE PANCREATIC INSUFFICIENCY; FEMALE; HUMANS; MALABSORPTION SYNDROMES; MALE; PANCRELIPASE; TABLETS, ENTERIC-COATED; TREATMENT OUTCOME; VITAMINS; YOUNG ADULT;

EID: 70450223534     PISSN: 15691993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcf.2009.07.006     Document Type: Article

References (44)

1. Kalnins D., Durie P.R., and Pencharz P. Nutritional management of cystic fibrosis patients. Curr Opin Clin Nutr Metab Care 10 3 (2007) 348-354
2. Kerem B.S., Buchanan J.A., Durie P., et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. Am J Hum Genet 44 (1989) 827-834
3. Durie P.R. Pancreatic aspects of cystic fibrosis and other inherited causes of pancreatic dysfunction. Med Clin North Am 84 (2000) 609-620
4. Shepherd R., Cooksley W.G., and Cooke W.D. Improved growth and clinical, nutritional, and respiratory changes in response to nutritional therapy in cystic fibrosis. J Pediatr 97 3 (1980) 351-357
5. Shepherd R.W., Holt T.L., Thomas B.J., et al. Nutritional rehabilitation in cystic fibrosis: controlled studies of effects on nutritional growth retardation, body protein turnover, and course of pulmonary disease. J Pediatr 109 5 (1986) 788-794
6. Dodge J.A. Malnutrition and age-specific nutritional management in cystic fibrosis. Neth J Med 41 3-4 (1992) 127-129
7. Thomson M.A., Quirk P., Swanson C.E., et al. Nutritional growth retardation is associated with defective lung growth in cystic fibrosis: a preventable determinant of progressive pulmonary dysfunction. Nutrition 11 4 (1995) 350-354
8. Pencharz P.B., and Durie P.R. Pathogenesis of malnutrition in cystic fibrosis, and its treatment. Clin Nutr 19 6 (2000) 387-394
9. Zemel B.S., Jawad A.F., FitzSimmons S., and Stallings V.A. Longitudinal relationship among growth, nutritional status, and pulmonary function in children with cystic fibrosis: analysis of the Cystic Fibrosis Foundation National CF Patient Registry. J Pediatr 137 3 (2000 Sep) 374-380
10. Steinkamp G., and Wiedemann B. Relationship between nutritional status and lung function in cystic fibrosis: cross sectional and longitudinal analyses from the German CF quality assurance (CFQA) project. Thorax 57 7 (2002) 596-601
11. Konstan M.W., Butler S.M., Wohl M.E., et al. Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis. J Pediatr 142 6 (2003) 624-630
12. FitzSimmons S.C. The changing epidemiology of cystic fibrosis. J Pediatr 122 1 (1993) 1-9
13. Cystic Fibrosis Foundation Patient Registry. Annual Data Report (2007), Bethesda, Maryland
14. Whitehead A.M. Study to compare the enzyme activity, acid resistance and dissolution characteristics of currently available pancreatic enzyme preparations. Pharm Weekbl Sci 10 1 (1988) 12-16
15. Kraisinger M., Hochhaus G., Stecenko A., Bowser E., and Hendeles L. Clinical pharmacology of pancreatic enzymes in patients with cystic fibrosis and in vitro performance of microencapsulated formulations. J Clin Pharmacol 34 2 (1994) 158-166
16. Case C.L., Henniges F., and Barkin J.S. Enzyme content and acid stability of enteric-coated pancreatic enzyme products in vitro. Pancreas 30 2 (2005) 180-183
17. Borowitz D., Durie P.R., Clarke L.L., et al. Gastrointestinal outcomes and confounders in cystic fibrosis. J Pediatr 146 2 (2005) 189-193
18. Smyth R.L., Ashby D., O'Hea U., et al. Fibrosing colonopathy in cystic fibrosis: results of a case-control study. Lancet 346 (1995) 1247-1251
19. Bakowski M.T., and Prescott P. Patterns of use of pancreatic enzyme supplements in fibrosing colonopathy: implications for pathogenesis. Pharmacoepidemiol Drug Saf 6 (1997) 347-358
20. FitzSimmons S.C., Burkhart G.A., Borowitz D., et al. High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosis. N Engl J Med 336 (1997) 1283-1289
21. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: exocrine pancreatic insufficiency drug products-submitting NDAs. April 2006. Available at: http://www.fda.gov/cder/guidance/6275fnl.htm. Accessed June 27, 2008.
22. Petersen W., Heilmann C., and Garne S. Pancreatic enzyme supplementation as acid-resistant microspheres versus enteric-coated granules in cystic fibrosis. A double placebo controlled cross-over study. Acta Paediatr Scand 76 (1987) 66-69
23. Robinson P.J., Olinsky A., Smith A.L., et al. High compared with standard dose lipase pancreatic supplement. Arch Dis Child 64 (1989) 143-145
24. Morrison G., Morrison J.M., Redmond A.O., et al. Comparison between a standard pancreatic supplement and a high enzyme preparation in cystic fibrosis. Aliment Pharmacol Ther 6 (1992) 549-555
25. Beker L.T., Fink R.J., Shamsa F.H., et al. Comparison of weight-based dosages of enteric-coated microtablet enzyme preparations in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 19 (1994) 191-197
26. Patchell C.J., Desai M., Weller P.H., et al. Creon 10,000 minimicrospheres vs. Creon 8,000 microspheres-an open randomised crossover preference study. J Cyst Fibros 1 4 (2002) 287-291
27. Borowitz D.S., Grand R.J., and Durie P.R. Use of pancreatic enzyme supplements for patients with cystic fibrosis in the context of fibrosing colonopathy, Consensus Committee. J Pediatr 127 (1995) 681-684
28. Borowitz D., Baker R.D., and Stallings V. Consensus report on nutrition for pediatric patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 35 (2002) 246-259
29. Henderson A.R., and Rinker A.D. Gastric, pancreatic, and intestinal function. In: Burtis C.A., and Ashwood E.R. (Eds). Tietz textbook of clinical chemistry. 3rd ed (1999), WB Saunders, Philadelphia 1293-1295
30. Sugai E., Srur G., Vazquez H., et al. Steatocrit: a reliable semiquantitative method for detection of steatorrhea. J Clin Gastroenterol 19 3 (1994) 206-209
31. Tran M., Forget P., Van den Neucker A., et al. The acid steatocrit: a much improved method. J Pediatr Gastroenterol Nutr 19 3 (1994) 299-303
32. Van den Neucker A.M., Kerkvliet E.M., Theunissen P.M., et al. Acid steatocrit: a reliable screening tool for steatorrhoea. Acta Paediatr 90 8 (2001) 873-875
33. Van den Neucker A.M., Forget P.P., and van Kreel B. Lipid, nitrogen, water and energy content of a single stool sample in healthy children and children with cystic fibrosis. Eur J Pediatr 162 11 (2003) 764-766
34. Benini L., Caliari S., Bonfante F., et al. Fecal fat concentration in the screening of steatorrhea. Digestion 53 1-2 (1992) 94-100
35. Amann S.T., Josephson S.A., and Toskes P.P. Acid steatocrit: a simple, rapid gravimetric method to determine steatorrhea. Am J Gastroenterol 92 12 (1997) 2280-2284
36. Cystic Fibrosis Therapeutic Development Network Coordinating C. Issue: response to the Data Safety Monitoring Board (December 30, 2005), Protocol Review Committee 1-3
37. Cystic Fibrosis F. Issue: DMC review decision (January 06, 2006), Data Safety Monitoring Board 1
38. Borowitz D. Update on the evaluation of pancreatic exocrine status in cystic fibrosis. Curr Opin Pulm Med 11 6 (2005) 524-527
39. Littlewood J.M., and Wolfe S.P. Control of malabsorption in cystic fibrosis. Paediatr Drugs 2 3 (2000) 205-222
40. Mischler E.H., Parrell S., Farrell P.M., and Odell G.B. Comparison of effectiveness of pancreatic enzyme preparations in cystic fibrosis. Am J Dis Child 136 (1982) 1060-1063
41. Konstan M.W., Stern R.C., Trout J.R., et al. Ultrase MT12 and Ultrase MT20 in the treatment of exocrine pancreatic insufficiency in cystic fibrosis: safety and efficacy. Aliment Pharmacol Ther 20 (2004) 1365-1371
42. Stern R.C., Eisenberg J.D., Wagener J.S., et al. A comparison of the efficacy and tolerance of pancrelipase and placebo in the treatment of steatorrhea in cystic fibrosis patients with clinical exocrine pancreatic insufficiency. Am J Gastroenterol 95 (2000) 1932-1938
43. Brady M.S., Garson J.L., Krug S.K., et al. An enteric-coated high-buffered pancrelipase reduces steatorrhea in patients with cystic fibrosis: a prospective, randomized study. J Am Diet Assoc 106 8 (2006) 1181-1186
44. Borowitz D., Goss C.H., Limauro S., et al. Study of a novel pancreatic enzyme replacement therapy in pancreatic insufficient subjects with cystic fibrosis. J Pediatr 149 5 (2006) 658-662